Global Lymphoma Drugs Market 2017-2021
About Lymphoma Drugs
Lymphoma is a type of cancer that affects the immune system of the body. Specifically, it affects the lymphocytes, a type of white blood cell. The lymphocytes are part of the immune system and help the body to fight infections. The cancerous lymphocytes grow uncontrollably and collect in different portions of the body; lymph node can be one of the most common sites for lymphoma development. The lymph nodes are found throughout the body particularly in the groin, neck, and under the arms. Lymphoma can also develop in the deeper lymph nodes such as those in bone marrow and spleen. Very rarely this disease can start in other parts of the body such as stomach, breast, skin, brain, bowel, or liver.
Technavio’s analysts forecast the global lymphoma drugs market to grow at a CAGR of 8.02% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global lymphoma drugs market for 2017-2021. To calculate the market size, the report considers the sales from branded, generic, and off-label drugs.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Lymphoma Drugs Market 2017-2021
Technavio recognizes the following companies as the key players in the global lymphoma drugs market: Celgene, F. Hoffmann-La Roche, Johnson & Johnson, and Seattle Genetics.
Other Prominent Vendors in the market are: Amgen, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Novartis, Pfizer, Takeda Pharmaceuticals, and Teva Pharmaceutical Industries.
Commenting on the report, an analyst from Technavio’s team said: “The latest trend gaining momentum in the market is increasing consolidation in the cancer treatment market. Past several years have witnessed significant consolidation in the cancer treatment industry. There can be seen a trend of movement of cancer treatment from clinics to hospitals. Studies have shown that there is a rise in a number of oncology clinics that got acquired by hospitals.”
According to the report, one of the major drivers for this market is increase in industry-academia collaborations. The key players in the market are increasingly extending their support to academic institutions to support the R&D of innovative drugs. Such collaborations enable the amalgamation of research expertise of academic institutions with the marketing intelligence of pharmaceutical companies, besides providing funds to conduct trial studies. For instance, Merck's cancer segment collaborated with academic institutions such as BioMed X to support R&D activities in the development of monoclonal antibodies (mAbs) for cancer segment.
Further, the report states that one of the major factors hindering the growth of this market is high cost of lymphoma treatment. The high cost of treatment is a major problem for the lymphoma patients across the globe. Many of the treatment options available for the individuals are out of their budget and ultimately forces the individual or the payer to skip the treatment. Virtual monopoly among the drug manufacturers and the high cost of R&D are some of the major factors for the high cost of lymphoma treatment. A large proportion of population either skip the treatment or leave it in the middle. Despite availing the costly treatment, reoccurrence of the disease quadruples the issues and negatively affects the patient adherence.
Celgene, F. Hoffmann-La Roche, Johnson & Johnson, Seattle Genetics, Amgen, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Novartis, Pfizer, Takeda Pharmaceuticals, and Teva Pharmaceutical Industries.